期刊文献+

某院肝炎或肝硬化患者质子泵抑制药应用合理性评价 被引量:1

Application and Rationality Evaluation of Proton Pump Inhibitors Used in Patients with Cirrhosis or Hepatitis in One Hospital
下载PDF
导出
摘要 目的:调查某院肝炎或肝硬化患者质子泵抑制药的使用情况,并进行合理性评价。方法:对某院2013~2014年诊断为“肝炎”或“肝硬化”的住院患者质子泵抑制药的应用情况进行回顾性分析,并对使用合理性进行评价。结果:共收集到211份病历,使用质子泵抑制药192例,使用率91%;不合理用药62例,占总病例数的29.3%;用药不合理主要表现为用药疗程过长(24.5%),预防用药指征不充分(5.7%),无目的用药(2.6%)。结论:肝炎或肝硬化患者质子泵抑制药的不合理使用十分普遍,临床药师应加强药学监护,促进合理用药。 Objective:To investigate the use of proton pump inhibitors ( PPIs) in the patients with cirrhosis or hepatitis in one hospital and evaluate the use rationality .Methods:A retrospective study was carried out on 211 patients with the diagnosis of hepatitis or cirrhosis in the infectious disease ward between 2013 and 2014 , and the use rationality of PPIs was evaluated .Results: A total of 211 cases were inspected, and among them, 192 ones were treated with PPIs (91%) with 62 ones treated with PPIs irrationally, which accounted for 29.3%of the total cases.The main irrational use of PPIs was long treatment course (24.5%), inadequate prophylaxis indications (5.7%) and purposeless use (2.6%).Conclusion: Irrational use of PPI is common in hepatitis or cirrhosis patients . Clinical pharmacists should strengthen pharmaceutical care to improve the rational drug use .
出处 《中国药师》 CAS 2016年第7期1342-1344,共3页 China Pharmacist
关键词 质子泵抑制药 肝炎 肝硬化 合理用药 Proton pump inhibitor Hepatitis Cirrhosis Rational drug use
  • 相关文献

参考文献5

二级参考文献103

  • 1傅翔,汪蓉.对国内近十年药物利用定量研究文献的分析[J].中国药师,2006,9(7):678-679. 被引量:4
  • 2凌明德 杜美娟.奥美拉唑在生殖系统的不良反应3例[J].新消化病学杂志,1996,4(3):161-161.
  • 3钱玉明.奥美拉唑引起严重脱发1例[J].新药与临床,1994,13(5):312-312.
  • 4Fulda TR, Lyles A, Pugh MC, et al. Current status of prospective drug utilization review [ J ]. J Manag Care Pharm ,2004,10(5 ) :433.
  • 5陈新谦 金有豫.新编药物学[M](第15版)[M].北京:人民卫生出版社,2000.90.
  • 6Gabriella der. An overview of proton pump inhibitors[J].Gastroenterology Nursing, 2003, 26(5):182.
  • 7Abelo A, Andersson TB, Antonsson M, et al. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes [J].Drug Metab Dispos, 2000, 28(8):966.
  • 8Kim KA, Kim MJ, Park JY, et al. Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes [J]. Drug Metab Dispos, 2003, 31(10):1227.
  • 9Horai TY. Cytochrome P450 and the metabolism of proton pump inhibitors emphasis on rabeprazole[J]. Aliment Pharmacol Ther, 1999, 13 (Suppl 3):27.
  • 10Li XQ, Tommy B, Ahlstrom M, et al. Comparison of inhibitory effects of the proton pump inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities[J]. Drug Metab Dispos, 2004, 32(8):821.

共引文献543

同被引文献4

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部